Opinion|Videos|April 29, 2024

Personalized Medicine: Optimizing Outcomes for Patients with CLL

Author(s)Rohit Gosain, MD, Rahul Gosain, MD, Nitin Jain, MD

Nitin Jain, MD, presents data on the efficacy of various chronic lymphocytic leukemia treatments, reviews current guidelines, discusses the increasing use of Bruton's tyrosine kinase inhibitors and the decreasing role of chemotherapy in his practice. He emphasizes the importance of considering patient factors and preferences in treatment decision-making.

Episodes in this series

Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides

EP. 1 Observation Versus Treatment for Patients with CLL

Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides

EP. 2 Personalized Medicine: Optimizing Outcomes for Patients with CLL

Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides

EP. 3 Comparing BTK Inhibitors for Optimal CLL Treatment

Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides

EP. 4 Advancing CLL Treatment: Latest Updates and Strategies

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

September 18th, 2026

Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL

"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.

Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.

September 16th, 2026

Does Venetoclax/Azacitidine Make Chemotherapy Obsolete in AML?

Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.

Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.

September 15th, 2026

How Does Azacitidine/Venetoclax Impact Hospital Burden in AML?

Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.

Trending on CancerNetwork

Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications

Acting on a HER2 Result and Navigating Access to Therapy

The Case for Frontline Zongertinib in HER2-Mutant NSCLC

Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC

Patient-Centered Treatment Transitions in HR+/HER2− mBC